Complication of Chronic Eosinophilic Pneumonia in an Elderly Patient with Sjögren Syndrome by Waseda, Koichi et al.
Complication of Chronic Eosinophilic Pneumonia in an Elderly 
Patient with Sjögren Syndrome
Koichi Waseda＊,  Hideharu Hagiya,  Yoshihisa Hanayama,  Tomohiro Terasaka,    
Kosuke Kimura,  Takao Tsuzuki,  Kou Hasegawa,  Takahiro Nada,    
Eri Nakamura,  Kazutoshi Murakami,  Eisei Kondo,  and Fumio Otsuka
Department of General Medicine,  Okayama University Graduate School of Medicine,   
Dentistry and Pharmaceutical Sciences,  Okayama 700-8558,  Japan
An 81-year-old Japanese male with primary Sjögren syndrome (pSS) developed a low-grade fever and 
productive cough which were refractory to antibiotic therapy.  Based on the high level of eosinophils 
observed in his bronchial alveolar lavage,  he was diagnosed with chronic eosinophilic pneumonia 
(CEP) and successfully treated by oral prednisolone. Interstitial lung diseases associated with pSS 
(pSS-ILDs) usually present as nonspeciﬁc interstitial pneumonia or usual interstitial pneumonia;  
therefore,   the present case is extremely unique in that the patientʼs condition was complicated with 
CEP. A diagnosis of advanced gallbladder cancer was made in the patientʼs clinical course,  suggesting 
the advisability of a whole-body workup in cases of pSS,  especially in elderly patients.
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rimary Sjögren syndrome (pSS) is an autoim-
mune disease characterized by the inﬁltration of 
lymphocytes in exocrine glands,  followed by hypofunc-
tion of the glands [1-3].  Nonspeciﬁc interstitial 
pneumonia (NSIP),  usual interstitial pneumonia (UIP) 
and lymphocytic interstitial pneumonia (LIP) are well 
known as representative patterns of interstitial lung 
diseases associated with primary Sjögren syndrome 
(pSS-ILDs).
　 CEP is an idiopathic interstitial lung disease 
caused by an accumulation of eosinophils in the lungs.  
The cause and pathophysiology of CEP have not been 
clariﬁed,  and the complication of chronic eosinophilic 
pneumonia (CEP) in patients with pSS-ILD has 
scarcely been reported.  Here we report the case of an 
elderly pSS patient who developed CEP and malig-
nancy.
Case Report
　 An 81-year-old Japanese male was admitted to our 
hospital due to pneumonia that was refractory to vari-
ous antibiotic therapies.  He had been diagnosed with 
pSS 3 years earlier and had been followed without 
any treatment.  He had suﬀered from a low-grade fever 
and productive cough for the prior 3 wks.  The patient 
consulted a general physician and was prescribed 
several antibacterial agents including cefepime,  mino-
cycline,  doripenem,  levoﬂoxacin and azithromycin 
under a diagnosis of bacterial pneumonia.  His condi-
tion,  however,  did not improve and he developed 
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progressing dyspnea.
　 His vital signs on arrival were as follows: body 
temperature,  38. 3℃; blood pressure,  123/76 mmHg;  
pulse rate,  83/min; respiratory rate,  ＞24/min; and 
oxygen saturation,  92ｵ (during oxygen inhalation of 
3L/min with nasal cannulas).  A physical examination 
revealed hyperpnea with inspiratory coarse crackles in 
both lungs.  Cardiac murmur was not observed.  A 
chest X-ray showed bilateral shadows,  and a chest 
computed tomography (CT) scan further demonstrated 
inﬁltrates in bilateral upper-dominant,  peripheral 
lungs (Fig.  1A).
　 In addition,  an abdominal plain CT scan showed 
some low-density areas (LDAs) in the liver (Fig.  1B).  
Arterial blood gases (oxygen inhalation of 5L/min 
with nasal cannulas) showed pH of 7.45,  PaO2 of 
162.6 Torr and PaCO2 of 29.1 Torr.  The patientʼs 
pulmonary function could not be measured due to the 
severity of his respiratory condition.  A laboratory 
examination (Table 1) revealed increased inﬂammation 
reaction (C-reactive protein,  CRP: 13.24mg/dL),  
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Table 1　 Laboratory data at admission to the hospital
WBC 11,580 /µl RF 35.3 IU/µl
Nt 81.1 % ANA ×80
Ly 6.9 % SS-A ＞240 U/ml
Mo 4.4 % SS-BB 27.5 U/ml
Eo 7.5 % PR3-ANCA (－)
Ba 0.1 % MPO-ANCA (－)
RBC 371 ×104/µl KL-6 304 U/ml
Hb 11.3 g/dl SP-D 231 ng/ml
PLT 44.2 ×104/µl CEA 5.57 ng/ml
T.Bil 0.65 mg/dl sIL-2R 1003 U/ml
AST 75 IU/I
ALT 88 IU/I β-D glucan ＜6.0 pg/ml
ALP 369 IU/I Aspergillus (－)
γ-GTP 67 IU/I Cryptococcus (－)
LDH 220 IU/I QFT-3G (－)
BUN 12.3 mg/dl U-Legionella (－)
Cr 0.70 mg/dl U-Pneumococcus (－)
CRP 13.24 mg/dl
A B
Fig. 1　 Chest and abdominal CT images: Bilateral,  upper lobe-predominant,  and peripheral consolidative and ground-glass opacities 
were shown by chest high-resolution CT (A).  Abdominal contrast-enhanced CT also revealed border irregularity and wall thickening of the 
gallbladder and ringed enhancement of LDAs in the liver (B).
leukocytosis (white blood cell count: 11,580/µL) with 
a left shift,  and moderate abnormality of liver func-
tions.  The serum level of the sialylated carbohydrate 
antigen KL-6 (KL-6) was within the normal range,  
and the serum levels of surfactant protein-D (SP-D:  
231ng/mL) and carcinoembryonic antigen (CEA:  
5.57ng/mL) were moderately elevated.  Serum beta-D 
glucan,  galactomannan antigen,  cryptococcal antigen 
and cytomegalovirus antigen were all negative.
　 Moderate peripheral blood eosinophilia was 
observed (868 counts/µL) and the serum IgE level 
was 44IU/mL (reference range ＜170IU/mL) on 
admission.  Anti-nuclear antibodies and rheumatoid 
factor were positive.  SS-A and SS-B,  indicating 
Sjögrenʼs syndrome,  were also conﬁrmed to be ele-
vated (＞240U/mL and 27.5U/mL,  respectively).  
Subsequently,  a labial minor salivary gland biopsy 
was performed,  and it revealed an atrophic gland with 
disappearance of acinar cells and a focal collection of 
lymphocytes.  Bronchial alveolar lavage (BAL) revealed 
an increased total cell number (8.5×105/mL) with a 
markedly high ratio of eosinophils (58ｵ) (Fig.  2).  
Two days later,  the peripheral blood eosinophil level 
was increased to 1,654 counts/µL.
　 Under a diagnosis of CEP,  oral prednisolone 
administration (50mg/day) was initiated,  and the 
patientʼs fever pattern,  respiratory symptoms and the 
chest inﬁltrates on radiography then improved rapidly.  
The dosage of prednisolone was gradually tapered to 
7.5mg/day for 3 months without recurrence (Fig.  3).
　 Twenty-one days after the initiation of the corti-
costeroid therapy,  pneumothorax occurred in the 
patientʼs right lung.  Contrast-enhanced CT revealed 
border irregularity and wall thickening of the gall-
bladder with ringed enhancement of LDAs in the liver 
(Fig.  1B).  Cytology and histology examinations 
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Fig. 2　 BAL ﬂuid revealed an increased total cell number with a 
markedly high ratio of eosinophils (58%).
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Fig. 3　 Clinical course of the patientʼs CEP treatment: The fever pattern,  cough,  dyspnea and chest imaging showed rapid improve-
ment by treatment with prednisolone (50mg/day).  The dosage was gradually reduced to 7.5mg/day for 3 months.  In the process of ther-
apy,  the patient developed pneumothorax and was diagnosed with gallbladder cancer.  Eos,  eosinophil count; SP-D,  surfactant protein-D.
revealed gallbladder cancer and multiple liver metas-
tases.
Discussion
　 Primary Sjögren syndrome (pSS) is a chronic 
inﬂammatory autoimmune disease characterized by 
decreased salivary and lacrimal gland function that is 
associated with lymphocytic inﬁltration of the exocrine 
glands.  Among the variety of extraglandular complica-
tions observed in pSS patients,  lung involvement is 
common with a prevalence of 9ｵ to 75ｵ [4-6].  The 
classiﬁcation of pSS-ILD is currently based on the 
2002 American Thoracic Society/European 
Respiratory Society consensus classiﬁcation of idio-
pathic interstitial pneumonias (2002 ATS/ERS clas-
siﬁcation of IIPs) [7].  Based on the results of a few 
studies focusing on pathologically proven pSS-ILD 
[8,  9],  the disease is generally associated with NSIP 
and UIP [10].  CEP secondary to pSS-ILD,  as seen 
in the present case,  is an extremely rare condition.
　 CEP was ﬁrst described by Carrington et al.  in 
1969 [11].  The disease is common among middle-aged 
women with an atopic history.  Asthma precedes CEP 
in one-half of the cases,  but the involvement of such a 
condition is not required for the development of CEP 
[12,  13].  Expected laboratory ﬁ ndings include ele-
vated inﬂammatory markers such as CRP and periph-
eral eosinophilia (seen in 80ｵ to 90ｵ of cases) [12].
　 A chest X-ray of a CEP patient generally shows 
bilateral peripheral shadows,  the so-called “photo-
graphic negative, ” showing a migratory pattern in the 
clinical course [11].  A high-resolution CT image 
exhibits bilateral,  upper lobe-predominant,  and 
peripheral consolidative and ground-glass opacities 
[12].  For the treatment of CEP,  corticosteroid 
therapy usually yields a marked improvement of symp-
toms and radiographic changes [13],  although a 
relapse may occur while the corticosteroid dose is 
tapered.  Some reports suggest that treatment with 
inhaled steroids may be of some value in this condition 
[14].
　 In our patient,  both the radiological ﬁndings and 
clinical course were consistent with CEP.  The level 
of peripheral blood eosinophils was moderately high on 
admission and increased further over the next 2 days.  
However,  the patient did not match the typical picture 
of the CEP population in that he was an elderly man 
without an atopic history.  The condition of pSS in the 
present case was stable; his dry eye symptoms were 
well controlled with eye drops and oral aerosolized 
drugs.  There was also no clinical impression that the 
use of several antibacterial agents prescribed by gen-
eral physicians caused the exacerbation of the patientʼs 
respiratory status.
　 Another interesting aspect of our patientʼs case was 
the complications of gallbladder cancer with multiple 
liver metastases.  It has been reported that T-cell 
lymphoma,  lung cancer,  prostate cancer,  gastric 
cancer,  colon cancer,  esophageal cancer,  malignant 
pleural mesothelioma and breast cancer,  excluding 
gallbladder cancer,  were complicated with eosinophil 
pneumonia [15,  16].  It was also reported that the 
activation of eosinophil-speciﬁc chemoattractants,  
including RANTES,  eotaxin,  and IL-5 released from 
Th2 lymphocytes in the lungs,  is involved in eosinophil 
accumulation in the lungs [13,  17,  18].  The involve-
ment of cytokines such as interleukin (IL)-3,  IL-5 and 
granulocyte-macrophage colony-stimulating factor 
(GM-CSF) produced by malignant cells in the devel-
opment of eosinophil pneumonia was also reported 
[19].  It is thus possible that our patient developed 
CEP as a paraneoplastic syndrome via the activation 
of some cytokines and chemokines induced by the 
gallbladder cancer.  If a similar patientʼs lung shadow 
worsens as prednisolone is tapered,  the serum levels 
of such cytokines should be investigated to clarify the 
relevance of the tumor.
　 In summary,  we treated an elderly patient with 
CEP that might have been related to his pSS and 
gallbladder cancer.  The present case suggests the 
necessity of a systemic work-up in cases of pSS,  
particularly in elderly patients with an atypical pulmo-
nary obstacle pattern.
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